CD8+ T cell activity (Cytotoxic T lymphocyte activity) (CTL activity)

CD8+ T cell activity represents the functional capacity of cytotoxic T lymphocytes (CTLs) to identify and eliminate compromised host cells, such as those infected by viruses or transformed into cancer cells (StatPearls, 2023). This process is mediated by the T-cell receptor (TCR) recognizing specific antigens presented on Major Histocompatibility Complex (MHC) class I molecules, followed by the secretion of cytotoxic molecules like perforin and granzymes to induce apoptosis (NIH, 2023). In many cancers, this activity is dampened by inhibitory signaling pathways, known as immune checkpoints, which tumors exploit to evade immune surveillance (Nature Reviews Cancer, 2012). Modern immunotherapies, such as PD-1/PD-L1 inhibitors, work by removing these "brakes" to reinvigorate CD8+ T cell activity against the tumor (PubMed, 2019). However, overactivation of these cells can lead to immune-related adverse events (irAEs), where the immune system attacks healthy tissues (Journal of Clinical Oncology, 2018). While CD8+ T cell activity is a critical endpoint in immunotherapy, it is considered a biological process or cellular state rather than a discrete molecular target like a single receptor or enzyme.

Other names

Cytotoxic T lymphocyte activityCD8+ T cell activationCTL responseCytotoxic T cell functionCD8+ effector function

Therapeutic modulation of CD8+ T cell activity occurs through several mechanisms: 1) Blockade of inhibitory checkpoint receptors (e.g., PD-1, CTLA-4) to prevent T cell exhaustion; 2) Agonism of costimulatory receptors (e.g., 4-1BB, OX40) to enhance activation; 3) Administration of stimulatory cytokines (e.g., IL-2, IL-15) to promote proliferation; and 4) Genetic engineering (e.g., CAR-T, TCR-T) to redirect specificity and potency (Nature, 2020; PubMed, 2021).